Funding Your Life Sciences Company in 2026

Unlike traditional startups, life sciences companies operate on longer timelines, require significantly more capital, and must navigate complex regulatory pathways before generating revenue. Scientific development progresses in stages, each requiring validation and funding. Clinical trials are expensive and time-consuming. Regulatory approvals can take years. These factors shape how investors evaluate opportunities and how companies must position themselves to succeed.

In the end, if a company cannot raise enough capital to reach its next milestone, it risks becoming what Ed Amer of Goodwin refers to as a ‘bridge to nowhere.’

Today’s Landscape

According to Jay Reilly of Foley Hoag LLP, 2026 has been a difficult year for raising money.

At a high level, there is still substantial capital flowing into the life sciences sector. However, that capital is increasingly concentrated in fewer companies. Investors are placing larger bets, but only on companies that demonstrate strong fundamentals and a clear path forward.

This has created a bifurcated market. On one side are well-positioned companies that continue to raise significant funding. On the other hand, companies are struggling to secure even modest investment.

“It’s still a matter of the have and have-nots,” observes Colin Kirby of Foley Hoag LLP. Capital is available, but it is far more selective. Companies that show progress and momentum are getting funded, while others are being left behind.

Investor Priorities

Deals are taking longer to close as investors conduct deeper diligence and seek greater certainty. This increased scrutiny means companies must be better prepared and more transparent throughout the fundraising process. Demonstrating clear advancement between funding rounds is critical. Jeffrey P. Bodle of Morgan, Lewis & Bockius LLP underscores the importance of scientific quality here. Without strong, credible science, a company will struggle to attract serious interest.

But science alone is not enough. Investors also look closely at the management team. They want to see experience, execution capability, and the ability to navigate the long and complex journey from development to commercialization. As Bodle notes, success requires a dedicated team that can see things through what is a long and complicated process.

Communicating With Investors

Fundraising is an ongoing process. The companies that succeed treat investor relationships as something to build over time, not just when they need capital. Engaging with potential investors before a formal raise allows companies to establish credibility and build familiarity so by the time they’re actively raising, they’re no longer starting from scratch.

Investors want to understand:

• What problem the company is solving
• How the science addresses that problem
• What milestones will be achieved with new capital
• How the company will create value

Consistency also matters. Regular updates, both good and bad, help build trust. Investors want to see progress, but they also appreciate transparency when challenges arise. Clear communication signals that management is thoughtful, organized, and in control.

Over time, these relationships compound. Investors who feel informed and engaged are far more likely to participate in future rounds, introduce new capital, and advocate on the company’s behalf.

In a competitive funding environment, strong relationships can be the difference between getting a deal done and coming up short.

Emerging Trends

The Growing Role of AI

Artificial intelligence is quickly becoming one of the most influential forces in life sciences funding. AI has the potential to speed up research, analyze massive datasets, and identify viable compounds more efficiently than traditional methods. In an industry where time and cost are major hurdles, that kind of advantage is hard to ignore.

As a result, companies leveraging AI are often seen as lower-risk, higher-upside opportunities. Many of the largest and most competitive funding rounds today are going to businesses that can clearly demonstrate how AI is improving their pipeline and increasing their chances of success.

Strategic Investors and Pharma Participation

Another important shift is the growing role of strategic investors, especially large pharmaceutical companies. Historically, startups were sometimes cautious about bringing in pharma partners too early, worried about losing control or limiting future options.

That mindset is changing.

Today, strategic investors are often viewed as valuable partners rather than constraints. In addition to providing capital, they bring industry expertise, validation, and potential pathways to commercialization. Having a recognized pharma company involved can also signal credibility to other investors.

In a more competitive funding environment, that combination of capital, experience, and strategic alignment can make a meaningful difference in a company’s ability to raise and grow.

Key Takeaways

• • Capital is available, but harder to access. Investors are deploying significant funds, but into fewer companies, making the market more competitive than ever.
  • Execution matters more than ever. Strong science is essential, but investors are equally focused on management teams that can deliver results and navigate complex development paths.
  • Milestones drive funding. Companies must raise enough capital to reach meaningful inflection points. Falling short can stall progress and jeopardize future funding.
  • AI is reshaping the landscape. Companies leveraging artificial intelligence, especially in drug discovery, are attracting increased attention and larger funding rounds.
  • Fewer deals, bigger bets. Investors are concentrating capital into a smaller number of high-conviction opportunities rather than spreading risk across many startups.
  • Fundraising takes longer. Increased diligence and selectivity mean longer timelines and more effort required to close rounds.
  • Strategic investors add value. Pharmaceutical companies and other strategic partners can provide not just capital, but credibility and potential paths to commercialization.
  • Structure matters. Understanding key legal and financial concepts, like dilution, valuation, and pay-to-play provisions, is critical to making informed decisions.
  • Relationships are critical. Ongoing communication and trust-building with investors can significantly impact fundraising success.
  • The fundamentals still win. Companies that demonstrate strong science, steady progress, and a clear path to value creation will continue to attract investment, even in a challenging market.

To learn more about this topic, view Current Issues in Funding your Life Sciences Company. The quoted remarks referenced in this article were made either during this webinar or shortly thereafter during post-webinar interviews with the panelists. Readers may also be interested to read other articles about start-ups & entrepreneurship.

This article was originally published on April 6, 2026.

©2026. DailyDAC^TM, LLC d/b/a/ Financial Poise^TM. This article is subject to the disclaimers found here.